Sesen Bio Inc (NASDAQ:SESN) Expected to Announce Earnings of -$0.08 Per Share

Wall Street analysts forecast that Sesen Bio Inc (NASDAQ:SESN) will report earnings per share of ($0.08) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sesen Bio’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.09). Sesen Bio reported earnings per share of ($0.09) in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The business is scheduled to report its next earnings report on Monday, March 2nd.

On average, analysts expect that Sesen Bio will report full-year earnings of ($0.91) per share for the current fiscal year, with EPS estimates ranging from ($0.92) to ($0.90). For the next fiscal year, analysts expect that the company will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.39) to ($0.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Sesen Bio.

Sesen Bio (NASDAQ:SESN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.01).

SESN has been the topic of several research reports. Laidlaw downgraded shares of Sesen Bio from a “buy” rating to a “hold” rating in a report on Friday, August 9th. Zacks Investment Research downgraded shares of Sesen Bio from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.25 price target on shares of Sesen Bio in a report on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $2.17.

A number of institutional investors have recently added to or reduced their stakes in the business. CVI Holdings LLC purchased a new stake in Sesen Bio in the 2nd quarter worth approximately $12,169,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Sesen Bio in the 2nd quarter worth approximately $31,000. Jane Street Group LLC purchased a new stake in Sesen Bio in the 2nd quarter worth approximately $48,000. D. E. Shaw & Co. Inc. purchased a new stake in Sesen Bio in the 2nd quarter worth approximately $32,000. Finally, Vanguard Group Inc. boosted its position in Sesen Bio by 0.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,554,563 shares of the company’s stock worth $5,332,000 after purchasing an additional 22,228 shares in the last quarter. Institutional investors and hedge funds own 22.49% of the company’s stock.

NASDAQ:SESN traded down $0.01 during midday trading on Wednesday, hitting $1.20. The company’s stock had a trading volume of 1,650,496 shares, compared to its average volume of 2,000,342. Sesen Bio has a fifty-two week low of $0.66 and a fifty-two week high of $2.60. The firm’s 50 day moving average is $1.20 and its 200-day moving average is $1.34. The firm has a market cap of $123.52 million, a P/E ratio of -2.18 and a beta of 0.72.

About Sesen Bio

Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

See Also: Blockchain

Get a free copy of the Zacks research report on Sesen Bio (SESN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sesen Bio (NASDAQ:SESN)

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.